MedPath

Phototherapy Combination With Topicals in Vitiligo

Not Applicable
Active, not recruiting
Conditions
Vitiligo, Generalized
Interventions
Combination Product: Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly
Combination Product: Calcipotriol/Betamethasone ointment plus NBUVB
Registration Number
NCT04440371
Lead Sponsor
Jordan University of Science and Technology
Brief Summary

Patients will be included in a randomized controlled clinical trial, will enroll only adult vitiligo patients with surface area of at least 10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH) and are planned to start on phototherapy Narrow Band Ultraviolet light B (NBUVB), regardless if they have previous treatment for their disease, one month wash off period will be given for patients who are already on phototherapy or other treatments for vitiligo.

Detailed Description

Patients to be included in this randomized controlled study are adults with generalized vitiligo of surface area of at least 10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH) and are planned to start on phototherapy Narrow Band Ultraviolet light B (NB-UVB), regardless if they have previous treatment for their disease, one month wash off period will be given for patients who are already on phototherapy or other treatments for vitiligo. In our going study, adult patients will be enrolled into 2 groups ( around 20 patients per each) in which NBUVB will be given 2-3 sessions per week in combination with one of the following randomly; one group will start on Tacrolimus 0.1% ointment twice daily, a second group will start on calcipotriol \& betamethasone containing cream once daily, photos will be taken and the exact sites involved will be detected, efficacy of treatment will be assessed according to repigmentation percentages of vitiligo areas from baseline at 3 and 6 months. The improvement at 6 months compared to baseline will be classified into 5 groups according to the percentage of repigmentation as follow; excellent (76%-100%); moderate (51%-75%); mild (26%-50%); minimal (1%-25%); or no response.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TacrolimusCalcipotriol/Betamethasone ointment plus NBUVBPhototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
calcipotriol / betamethasoneCalcipotriol/Betamethasone ointment plus NBUVBPhototherapy NBUVB will be given 3 times per week and calcipotriol \& betamethasone containing cream will be applied once a day
TacrolimusTacrolimus 0.1% ointment twice daily plus NBUVB 3 times weeklyPhototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
calcipotriol / betamethasoneTacrolimus 0.1% ointment twice daily plus NBUVB 3 times weeklyPhototherapy NBUVB will be given 3 times per week and calcipotriol \& betamethasone containing cream will be applied once a day
Primary Outcome Measures
NameTimeMethod
efficacy of treatmentBaseline: measurement of vitiligo BSA with photographs of vitiligo areas. lab investigations done at this stage

The area of vitiligo will be measured using body surface area (BSA) at baseline. the difference in BSA will represent the improvement from baseline. Patient palm will be used for estimation of BSA at each visit (Each one plam is equivalent to 1% of BSA). Photographs will be taken .

Efficacy of treatment6 months post treatment

The area of vitiligo will be measured using body surface area (BSA). the difference in BSA will represent the improvement from baseline. Patient palm will be used for estimation of BSA at each visit (Each one plam is equivalent to 1% of BSA). Photographs will be taken.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Diala Alshiyab

🇯🇴

Irbid, Jordan

© Copyright 2025. All Rights Reserved by MedPath